GlassScriptPhysician profile
Bhadresh A Patel
NPI 1336115534
$3,531.40
in general payments reported to CMS, 2019-2025
27 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $597 · 2021: $162 · 2022: $490 · 2023: $892 · 2024: $714 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $707.95 | 2019-2025 | |
| Artivion, INC. | $554.80 | 2020 | |
| Impulse Dynamics (USA) INC. | $334.38 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $295.86 | 2019-2024 | Xarelto, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $243.99 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.06 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $233.69 | 2022-2025 | Verquvo |
| Abbott Laboratories | $164.67 | 2019-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $123.01 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $73.31 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lantheus Medical Imaging, INC. | $64.33 | 2020-2022 | |
| Medtronic, INC. | $56.27 | 2023-2024 | Micra, Azure Xt Dr Mri Surescan |
| Akcea Therapeutics, INC. | $52.33 | 2019 | |
| Kestra Medical Technology Services, INC. | $50.10 | 2023 | Assure Wcd |
| Amgen INC. | $46.17 | 2023-2025 | Repatha, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $44.44 | 2019-2025 | Lifevest |
| Abiomed | $44.03 | 2024 | Impella |
| Boston Scientific Corporation | $42.21 | 2020-2024 | Watchman Access System |
| Pfizer INC. | $30.06 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $24.72 | 2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $20.57 | 2019 | |
| Astellas Pharma US INC | $15.24 | 2022 | |
| Amarin Pharma, INC. | $15.11 | 2022 | |
| Edwards Lifesciences Corporation | $14.31 | 2023 | |
| Ge Healthcare | $14.14 | 2019 | |
| Csl Behring | $13.82 | 2019 | |
| Medtronic Vascular, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhadresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.